Enzymotec Ltd (NASDAQ:ENZY), reported first quarter non-GAAP EPS of $0.24 Wednesday morning, compared to $0.12 last year. Analysts expected EPS of $0.17. The company now expects full year 2014 non-GAAP EPS of $0.64 to $0.94. The consensus estimate is for EPS of $0.86. Enzymotec gapped open lower Wednesday and has spiked to the downside in early trade. The stock is currently lower by 4.73 at $15.50 and has plunged to over a 7-month low. Enzymotec Ltd (NASDAQ:ENZY), net profit margin is 11.70% and weekly performance is -29.16%. On last trading day company shares ended up $13.75. Analysts mean target price for the company is $29.00. Enzymotec Ltd (NASDAQ:ENZY), distance from 50-day simple moving average (SMA50) is -38.58%.
On Amy 08, 2014, DARA Biosciences Inc (NASDAQ:DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, announced that Soltamox has been added to the Federal Supply Schedule for purchase by all government agencies. DARA Biosciences Inc (NASDAQ:DARA), fell 10.41% in last trading session and ended the day on $1.12. DARA, Gross Margin is 50.00% and its return on assets is -107.20%. DARA Biosciences Inc (NASDAQ:DARA), quarterly performance is -56.08%.
On May 01, 2014, Acasti Pharma Inc (NASDAQ:ACST), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announced that it will be presenting at two upcoming scientific forums. The presentations will be on Acasti’s Phase II Open Label (COLT) trial results, previously announced in August 2013. Acasti Pharma Inc (NASDAQ:ACST), shares moved down 4.30% in last trading session and was closed at $0.890, while trading in range of $0.89 – 0.95. Acasti Pharma Inc (NASDAQ:ACST), year to date (YTD) performance is -28.80%.
Onconova Therapeutics Inc (NASDAQ:ONTX), issued its quarterly earnings data on Tuesday. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by $0.09, Stock Ratings Network reports. Onconova Therapeutics Inc (NASDAQ:ONTX), ended the last trading day at $5.16. Company weekly volatility is calculated as 4.18% and price to cash ratio as 1.12. Onconova Therapeutics Inc (NASDAQ:ONTX), showed a negative weekly performance of 4.27%.
On May 07, 2014, Targacept , Inc. (NASDAQ:TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, reported its financial results for the first quarter ended March 31, 2014. Targacept reported a net loss before income taxes of $11.6 million for the first quarter of 2014, compared to a net loss before income taxes of $8.1 million for the first quarter of 2013. As of March 31, 2014, cash and investments in marketable securities totaled $132.1 million. Targacept , Inc. (NASDAQ:TRGT), weekly performance is -8.76%. On last trading day company shares ended up $3.75. Analysts mean target price for the company is $4.25. Targacept , Inc. (NASDAQ:TRGT), distance from 50-day simple moving average (SMA50) is -17.23%.
Leave a Reply